Abstract
The non-inferiority (NI) trial is designed to show that an experimental treatment is not worse than an active reference by more than a pre-specified margin. Traditional NI trials do not include a placebo for ethical reasons; however, three-arm NI trials consisting of placebo, reference, and experimental treatment, can test the NI of experimental treatment to the reference while assessing the superiority of the reference over placebo. Assay sensitivity (AS) of a clinical trial is defined as its ability to distinguish between an effective and ineffective treatment and has been used to assess the superiority of the reference over placebo. Bayesian approaches have been predominantly used in clinical trials, particularly in NI trials. Most previous Bayesian approaches have focused on parametric priors of treatment effects. Restriction to parametric priors can mislead investigators into an inappropriate illusion of posterior certainty, leading to misleading decisions and inference. In this paper, we develop a novel semiparametric Bayesian approach to simultaneously assess NI of experimental treatment over the reference and AS of the reference over placebo in a three-arm trial with normally distributed endpoints. We use Dirichlet process priors to specify the priors of treatment effects. A Markov chain Monte Carlo algorithm is developed to calculate the posterior probability for assessing NI and AS. Simulation studies show that our proposed method is comparable to, or better than, the frequentist approach and parametric Bayesian methods in terms of the ability of controlling the type I errors and empirical statistical powers for testing NI. Data from two real trials are illustrated by the proposed methods. We recommend the usage of the proposed method in a three-arm trial.
Similar content being viewed by others
References
Arnold BC, Beaver RJ, Groeneveld RA et al (1993) The nontruncated marginal of a truncated bivariate normal distribution. Psychometrika 58(3):471–488
Barnes TG III, Jefferys W, Berger J et al (2003) A Bayesian analysis of the cepheid distance scale. Astrophys J 592(1):539
Caron F, Davy M, Doucet A et al (2007) Bayesian inference for linear dynamic models with dirichlet process mixtures. IEEE Trans Sig Process 56(1):71–84
Chan IS, Tang NS, Tang ML et al (2003) Statistical analysis of noninferiority trials with a rate ratio in small-sample matched-pair designs. Biometrics 59(4):1170–1177
Chen MH, Ibrahim JG, Lam P et al (2011) Bayesian design of noninferiority trials for medical devices using historical data. Biometrics 67(3):1163–1170
Chow SM, Tang N, Yuan Y et al (2011) Bayesian estimation of semiparametric nonlinear dynamic factor analysis models using the dirichlet process prior. Br J Math Statist Psychol 64(1):69–106
Doi M, Takahashi F, Kawasaki Y (2017) Bayesian noninferiority test for 2 binomial probabilities as the extension of fisher exact test. Statist Med 36(30):4789–4803
FDA U (2010) Draft guidance for industry: Non-inferiority clinical trials. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf
Ghosh P, Nathoo F, Gönen M et al (2011) Assessing noninferiority in a three-arm trial using the Bayesian approach. Statist Med 30(15):1795–1808
Ghosh S, Ghosh S, Tiwari RC (2016) Bayesian approach for assessing non-inferiority in a three-arm trial with pre-specified margin. Stat Med 35(5):695–708
Ghosh S, Paul E, Chowdhury S, et al (2020) New approaches for testing non-inferiority for three-arm trials with poisson distributed outcomes. Biostatistics
Group IEEW et al (1999) Ich harmonised tripartite guideline: statistical principles for clinical trials. Stat Med 18(15):1905–1942
Guindani M, Sepúlveda N, Paulino CD et al (2014) A bayesian semi-parametric approach for the differential analysis of sequence counts data. J Royal Statist Soc Ser C Appl Stat 63(3):385
Ibrahim JG, Chen MH (2000) Power prior distributions for regression models. Stat Sci pp 46–60
Li W, Chen MH, Wang X et al (2018) Bayesian design of non-inferiority clinical trials via the Bayes factor. Stat Biosci 10:439–459
Pigeot I, Schäfer J, Röhmel J et al (2003) Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. Stat Med 22(6):883–899
Rosner GL (2005) Bayesian monitoring of clinical trials with failure-time endpoints. Biometrics 61(1):239–245
Sankoh AJ (2008) A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial. Stat Med 27(19):3732–3742
Selhuraman J (1994) A constructive definition of the dirichlet prior. Stat Sinica 2:639–650
Tang AM, Tang NS (2015) Semiparametric Bayesian inference on skew-normal joint modeling of multivariate longitudinal and survival data. Stat Med 34(5):824–843
Tang ML, Tang NS (2004) Tests of noninferiority via rate difference for three-arm clinical trials with placebo. J Biopharm Stat 14(2):337–347
Tang ML, Tang NS, Chan IS (2005) Confidence interval construction for proportion difference in small-sample paired studies. Stat Med 24(23):3565–3579
Tang N, Yu B (2022) Bayesian sample size determination in a three-arm non-inferiority trial with binary endpoints. J Biopharm Stat 32(5):768–788
Tang NS, Tang ML, Chan ISF (2003) On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 22(8):1217–1233
Tang NS, Tang AM, Pan DD (2014) Semiparametric Bayesian joint models of multivariate longitudinal and survival data. Comput Stat Data Anal 77:113–129
Tang NS, Yu B, Tang ML (2014) Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints. BMC Med Res Methodol 14(1):1–9
Tango T (1998) Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 17(8):891–908
Yusof ZM, Azmee NA (2015) A narrative review of two-arm and three-arm non-inferiority clinical trials. J Sci Math Lett 3:24–30
Acknowledgements
The authors are grateful to the Editor, an Associate Editor and two anonymous referees for their constructive suggestions that greatly improved this manuscript. This work was supported by grants from the National Natural Science Foundation of China (No. 12271472), and the National Key R &D Program of China (No. 102022YFA1003701).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix A Conditional distributions required for implementing Gibbs sampler
Appendix A Conditional distributions required for implementing Gibbs sampler
Steps (i)-(vi): Conditional distributions related to joint posterior distribution of \(\mu _R\) and \(\mu _P\)
Step (i). Conditional distribution of \(\mu _{kz}\) given \(Z_k,\psi _{kz},\mu _{0kz},\phi _{0kz}\) is
where \(\psi _{k\mu }=(G\psi _{kz}^{-1}+\phi _{0kz}^{-1})^{-1}\), \(\mu _{k\mu }=\psi _{k\mu }\{\phi _{0kz}^{-1}\mu _{0kz}+\psi _{kz}^{-1}\sum _{g=1}^GZ_{kg}\}\).
Step (ii). Conditional distribution of \(\psi _{kz}\) given \(Z_k,\mu _{kz}, c_{k1}\) and \(c_{k2}\) is
where \(Z_{kg}\) is the value of \(Z_k\) associated with cluster g.
Step (iii). Conditional distribution \(\tau _k\) given \((\pi _k,a_{k1},a_{k2})\) is
where \(v_{kg}^*\) is the random weight sampled from beta distribution, and is drawn within Step (iv).
Step (iv). As \(\pi _k\) given \(\tau _k\) is independent of \(Z_k\) given \((X_k,\sigma _k^2)\), the conditional distribution \(f(\pi _k,Z_k\mid \mathcal {L}_k,\mu _{kz},\psi _{kz},\tau _k,{\sigma _k^2},X_k)\) is proportional to \(f(\pi _k\mid \mathcal {L}_k,\tau _k)f(Z_k\mid \mathcal {L}_k\), \(\mu _{kz},\psi _{kz},\sigma _k^2,X_k)\). Thus, the conditional distribution of \((\pi _k,Z_k)\) can be decomposed into two independent components to be derived separately.
Conditional distribution \(f(\pi _k\mid \mathcal {L}_k,\tau _k)\). It can be shown that conditional distribution \(f(\pi _k\mid \mathcal {L}_k,\tau _k)\) is a generalized Dirichlet distribution:
where \(a_{kg}^*=1+d_{kg}\), \(b_{kg}^*=\tau _k+\sum _{j=g+1}^{G}d_{kj}\) for \(g=1,\dots ,G-1\), and \(d_{kg}\) is the number of \(\mathcal {L}_{ki}\)s whose value equals g. Sampling from \(f(\pi _k\mid \mathcal {L}_k,\tau _k)\) can be implemented as follows. First, \(v_{kg}^*\) is drawn from a Beta\((a_{kg}^*,b_{kg}^*)\) distribution. Next, \(\pi _{kg}\)’s are obtained as
Conditional distribution \(f(Z_k\mid \mathcal {L}_k,\mu _{kz},\psi _{kz},{\sigma _k^2},X_k)\) can be decomposed as
which leads to
where \(\psi _{kL}=(\psi _{kz}^{-1}+n_k\sigma _k^{-1})^{-1}\), and \(\mu _{kL}=\psi _{kL}(\sigma _{kz}^{-1}\mu _{kz}+\sigma _k^{-1}\sum {X_{ki}})\).
Step (v). The conditional distribution \(f(\mathcal {L}_{k}\mid \pi _k,Z_k,X_k)\) is given by
where \(\pi _{kg}^*\) is proportional to \(\pi _{kg}\prod _{i=1}^np\left( X_{ki}\mid \mu _k=Z_{k{\mathcal {L}_k}},\sigma _k^2\right)\), and \(\pi _{kg}\)’s are available from step (iv).
Step (vi). Conditional distribution \(f(\sigma _k^2\mid Z_{k\mathcal {L}_k},X_k,\mathcal {G}_{k1},\mathcal {G}_{k2})\) is
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tang, N., Liang, F. & Jiang, D. Semiparametric Bayesian approach to assess non-inferiority with assay sensitivity in a three-arm trial with normally distributed endpoints. Comput Stat 39, 2157–2181 (2024). https://doi.org/10.1007/s00180-023-01384-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00180-023-01384-y